Skin toxicity after administration of low-dose cytarabine.
Kantar
M
M
Department of Pediatric Oncology, Ege University Faculty of Medicine, Bornova, Izmir, Turkey.
Cetingül
N
N
Oniz
H
H
Aydinok
Y
Y
Kavakli
K
K
D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects*; D002648:Child; D003561:Cytarabine / Q000009:adverse effects*; D004893:Erythema Nodosum / Q000139:chemically induced; D005076:Exanthema / Q000139:chemically induced; D005260:Female; D006801:Humans; D007223:Infant; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy; D008297:Male; D012871:Skin Diseases / Q000139:chemically induced*; D014581:Urticaria / Q000139:chemically induced
D000964:Antimetabolites, Antineoplastic; D003561:Cytarabine